BioCentury
ARTICLE | Company News

Helsinn, Mundipharma deal

February 16, 2015 8:00 AM UTC

Helsinn granted Mundipharma exclusive, Brazilian commercialization rights to NEPA. The fixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) Substance P receptor antagonist, and 0.5 mg ...